Browsing Tag
Medtronic
32 posts
Boston Scientific (BSX) Q2 2026 beats estimates as MiRus TAVR investment reshapes strategy
Boston Scientific lifted FY 2026 guidance and disclosed a $1.5B MiRus TAVR bet, but BSX trades near 52-week lows as softer Q3 growth guidance stings.
Catheter Precision (VTAK) rallies 122% on new patents and Flyte 1,000 user milestone
Catheter Precision (VTAK) rallies 122% as two new patents and Flyte hits 1,000 users boost pivot story. Going concern warning still shadows the rally.
Saluda Medical wins CAP24 FDA approval as ASX:SLD shares rally 22%
Discover how Saluda Medical’s CAP24 FDA approval may expand Evoke adoption, reshape SCS competition and test ASX’s execution. Read the analysis in full.
Why does Danaher (DHR) completing the Masimo acquisition matter for diagnostics and patient monitoring?
Find out how Danaher’s $9.9bn Masimo acquisition could reshape DHR’s diagnostics growth, medtech competition and investor sentiment.
Insulet Omnipod 6 data puts PODD back in focus as automated insulin delivery moves toward type 2 diabetes
Read how Insulet Omnipod 6 data could reshape automated insulin delivery, type 2 diabetes care and PODD stock sentiment. Find out what changes next in 2026.
DexCom (DXCM) gains strategic evidence edge as CONNECT study targets broader diabetes market
Find out how DexCom’s CONNECT study could expand CGM use in non-insulin Type 2 diabetes and reshape DXCM’s growth outlook.
Anteris Technologies (ASX: AVR) stock up 9.6% as PARADIGM trial reaches first US patient enrolments
Edwards and Medtronic own TAVR. Anteris (ASX: AVR) wants in with DurAVR. First US PARADIGM patients enrolled, US$320m raised, and Medtronic is now a shareholder.
Why the $11.5bn global sutures market is splitting into two growth stories
Sutures look like a mature commodity. Antimicrobial coatings, ambulatory surgery and Asia-Pacific demand are quietly turning it into a margin contest.
Boston Scientific to acquire Penumbra for $14.5bn in transformative vascular and neurovascular expansion move
Boston Scientific’s $14.5B acquisition of Penumbra signals an aggressive move into neurovascular and thrombectomy markets. Find out what this means for medtech.
Can Nia’s 60-channel brain implant redefine closed-loop neuromodulation in memory therapy?
Nia Therapeutics validates its wireless brain implant for closed-loop memory stimulation. Find out how it could transform treatment for traumatic brain injury.